Drugs / Canocapavir
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05470829 | May → Nov 2021 | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04220801 | Feb → Nov 2020 | — | Shanghai Zhimeng Biopharma, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05484466 | Nov → Dec 2022 | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07095855 | Aug 2025 → Jan 2028 expected | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Canocapavir | “A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in...” NCT07095855 ↗2“Canocapavir (ZM-H1505R) is a small-molecule hepatitis B virus capsid assembly modulator with a novel pyrazole structure.” PMID 39132049 ↗ Jan 2023 “ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were evaluated in patients with CHB.” PMID 36927420 ↗ Mar 2023 |
| Known as | ZM-H1505R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05484466 ↗ |
| Modality | Small molecule | “Canocapavir (ZM-H1505R) is a small-molecule hepatitis B virus capsid assembly modulator” PMID 39132049 ↗ Jan 2023 |
| Route | Oral | “following oral administration in healthy subjects” NCT04220801 ↗ |